Who founded Pardes Biosciences?

Pardes Biosciences was founded by Uri Lopatin, Uri A. Loptain in 2020.

Who are Pardes Biosciences's investors?

Pardes Biosciences's investors include Y Combinator, Foresite Capital, Khosla Ventures.

How much funding has Pardes Biosciences raised?

Pardes Biosciences has disclosed $51.6M raised across 1 round.

Where is Pardes Biosciences headquartered?

Pardes Biosciences is headquartered in San Francisco, US.

Pardes Biosciences

YC S20YC Top Company

San Francisco, US · Founded 2020 · Delaware corporation · 2 employees · Public · 3 known investors

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

Biotech Healthtech TherapeuticsUnited States of AmericaAmerica / CanadaFully Remote

Founders & leadership· Y Combinator alumni (S20)

Pardes Biosciences was founded in 2020 by Uri Lopatin and Uri A. Loptain.

Uri Lopatin inFounder, Board Member, Strategic and Scientific Advisor2022–2023Uri Lopatin co-founded Assembly Pharma and served as Chief Medical Officer before its merger with Assembly Biosciences in 2014, where he held the role of CMO and VP of R&D and oversaw clinical development of hepatitis B antivirals. He previously worked as a physician-researcher at Schering Plough, Roche, and Gilead Sciences, and completed medical training at UMDNJ, NYU, and the NIH.

Uri A. LoptainCo-founder

Heidi HensonExecutive

Elizabeth LacyExecutive

Lee ArnoldExecutive

Board

J. Jay LobellBoard director

James B. TananbaumBoard director

Mark AueurbachBoard director

Michael D. VarneyBoard director

Investors · 3

Y CombinatorSan Francisco · $500K

Foresite CapitalreportedWest Hollywood

Khosla VenturesreportedMenlo Park · $5K – $50M

Reported raises · per SEC filings

Form D private placements

$51.6M disclosed across 1 round · 2021

▶$51.6MraisedFeb 2021 · 36 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Uri A. LoptainExecutive Officer, Director
Mark AueurbachDirector
Michael D. VarneyDirector
J. Jay LobellDirector
Heidi HensonExecutive Officer
Elizabeth LacyExecutive Officer
Lee ArnoldExecutive Officer
James B. TananbaumDirector

Offering amount: $51.6M
Amount sold: $51.6M
First sale: Jan 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Pardes Biosciences nets $199 million in COVID-19 pill race - Los Angeles Timeslatimes.com · Dec 2021

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19globenewswire.com · Dec 2021

Frequently asked questions

What does Pardes Biosciences do?: Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.
Who founded Pardes Biosciences?: Pardes Biosciences was founded by Uri Lopatin, Uri A. Loptain in 2020.
Who are Pardes Biosciences's investors?: Pardes Biosciences's investors include Y Combinator, Foresite Capital, Khosla Ventures.
How much funding has Pardes Biosciences raised?: Pardes Biosciences has disclosed $51.6M raised across 1 round.
Where is Pardes Biosciences headquartered?: Pardes Biosciences is headquartered in San Francisco, US.